America’s $93 billion pipeline of generic pharmaceuticals often starts in places like Toansa, a village in northern India where a drug-making facility rises up beside mustard fields and manure-flecked ox-cart tracks.
Regeneron Pharmaceuticals Inc. and Sanofi and must assess how their experimental cholesterol drug affects brain function after U.S. regulators learned of adverse events associated with this new class of medicines.
Alzheimer’s, known mostly for the memory loss and confusion it causes, may be the nation’s third- most deadly killer, according to a study that suggests many more Americans die from the disease than is known.
Aiming deep inside the brain, drugmakers are testing medicines that may improve learning in people with Down syndrome, an advance unimaginable 50 years ago when many children with the genetic condition were considered hopelessly disabled.
In China, there are only about 300 qualified physicians to treat more than 9 million dementia sufferers. The shortage is overwhelming families and threatening resources from an already stretched welfare system as the country ages.
About 1 in 8 Americans at least 60 years old reported confusion or memory loss in the preceding 12 months, according to health officials highlighting the need to be alert for early signs of dementia or Alzheimer’s disease.
Age-related forgetfulness may be due to a deficiency in a brain protein that helps form memories, a study found. Targeting the gene that produces that protein could lead to new therapies, the researchers said.